Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Problems with long-term levodopa therapy for Parkinson's disease

C D Marsden1

  • 1University Department of Clinical Neurology, National Hospital for Neurology & Neurosurgery, Queen Square, London, England.

Clinical Neuropharmacology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson's disease.

Journal of neurology, neurosurgery, and psychiatry·1992
Same author

New insights into the cause of Parkinson's disease.

Neurology·1992
Same author

Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group.

Annals of neurology·1992
Same author

Fronto-striatal cognitive deficits at different stages of Parkinson's disease.

Brain : a journal of neurology·1992
Same author

Corticobasal degeneration.

Bailliere's clinical neurology·1992
Same author

"Isolated" postinfectious myoclonus.

Journal of neurology, neurosurgery, and psychiatry·1992
Same journal

Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.

Clinical neuropharmacology·2026
Same journal

Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.

Clinical neuropharmacology·2026
Same journal

Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study.

Clinical neuropharmacology·2026
Same journal

A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.

Clinical neuropharmacology·2026
Same journal

Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.

Clinical neuropharmacology·2026
Same journal

Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.

Clinical neuropharmacology·2026
See all related articles

Levodopa revolutionized Parkinson's disease management but offers only symptomatic relief and causes adverse effects. Strategies aim to delay complications, balancing symptom control with managing side effects like fluctuations and dyskinesias.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Levodopa significantly advanced Parkinson's disease (PD) treatment.
  • However, levodopa provides symptomatic relief without altering PD pathology.
  • Chronic levodopa use leads to significant adverse effects and treatment complications.

Purpose of the Study:

  • To review current therapeutic strategies for Parkinson's disease.
  • To discuss the long-term adverse effects of levodopa therapy.
  • To outline management approaches for levodopa-induced complications.

Main Methods:

  • Literature review of Parkinson's disease management.
  • Analysis of levodopa's efficacy and adverse effects over time.
  • Discussion of pharmacological and non-pharmacological interventions.

Related Experiment Videos

Main Results:

  • Long-term levodopa therapy (≥5 years) frequently results in motor fluctuations, dyskinesias, toxicity, or loss of efficacy.
  • Motor fluctuations can be managed by adjusting the levodopa regimen (e.g., Sinemet, Sinemet CR) or adding deprenyl or dopamine agonists.
  • Dyskinesias are challenging to manage, though dopamine agonists may offer some benefit.

Conclusions:

  • Current Parkinson's disease management focuses on delaying levodopa complications.
  • Therapeutic choices must balance symptomatic relief with the patient's tolerance for adverse effects.
  • Effective management of levodopa-induced side effects is crucial for long-term patient care.